Thyrocare Technologies Tidigare resultatutveckling
Tidigare kriterier kontrolleras 5/6
Thyrocare Technologies s intäkter har minskat med en genomsnittlig årlig takt på -8%, medan Healthcare -branschen såg intäkter på växande på 25.3% årligen. Intäkterna har varit växande med en genomsnittlig takt på 7.5% per år. Thyrocare Technologies s avkastning på eget kapital är 27.8% och den har en nettomarginal på 19.7%.
Viktig information
-7.98%
Tillväxttakt i vinsten
-8.19%
Tillväxttakt för EPS
| Healthcare Tillväxt i branschen | 29.41% |
| Intäkternas tillväxttakt | 7.48% |
| Avkastning på eget kapital | 27.79% |
| Nettomarginal | 19.67% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Jun 04
539871: Expanded Healthcare Objects Clause Will Support Bullish Medium Term View
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹600, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. This indicates that the latest review did not alter their fundamental valuation framework for the stock.Uppdatering av berättelse • May 18
539871: Expanded Healthcare Mandate Will Support Bullish Medium Term View
Analysts have lifted their price target on Thyrocare Technologies from ₹571.67 to ₹600.00, and point to updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple as key drivers of the change. What's in the News The Board has approved changes to the Memorandum of Association to align it with the Companies Act, 2013, including updated references and clauses linked to current regulations (Key Developments).Uppdatering av berättelse • Apr 28
539871: Stable Return Assumptions Will Support Bullish Medium Term View
Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.Uppdatering av berättelse • Apr 09
539871: Stable Assumptions And Upcoming Results Will Support Bullish View
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 25
539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook
Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.Uppdatering av berättelse • Mar 11
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Feb 24
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Feb 10
539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns
Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Jan 26
539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns
Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Jan 10
539871: Stock Split And Bonus Share Flexibility Will Support Future Returns
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).Uppdatering av berättelse • Dec 26
539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns
Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).Uppdatering av berättelse • Dec 11
539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value
Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.Uppdatering av berättelse • Nov 27
539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.Uppdatering av berättelse • Nov 12
539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).Uppdatering av berättelse • Oct 29
Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).Uppdatering av berättelse • Oct 15
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.Uppdatering av berättelse • Sep 05
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Ny berättelse • Jan 26
Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader
Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Thyrocare Technologies tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 8,290 | 1,630 | 447 | 0 |
| 31 Dec 25 | 7,923 | 1,375 | 212 | 0 |
| 30 Sep 25 | 7,626 | 1,276 | 212 | 0 |
| 30 Jun 25 | 7,235 | 1,063 | 212 | 0 |
| 31 Mar 25 | 6,874 | 915 | 217 | 0 |
| 31 Dec 24 | 6,544 | 877 | 209 | 0 |
| 30 Sep 24 | 6,233 | 840 | 209 | 0 |
| 30 Jun 24 | 5,939 | 776 | 0 | 0 |
| 31 Mar 24 | 5,719 | 708 | 209 | 0 |
| 31 Dec 23 | 5,535 | 655 | 121 | 0 |
| 30 Sep 23 | 5,468 | 648 | 121 | 0 |
| 30 Jun 23 | 5,338 | 599 | 121 | 0 |
| 31 Mar 23 | 5,267 | 645 | 121 | 0 |
| 31 Dec 22 | 5,214 | 731 | 83 | 0 |
| 30 Sep 22 | 5,108 | 800 | 83 | 0 |
| 30 Jun 22 | 5,520 | 1,423 | 83 | 0 |
| 31 Mar 22 | 5,889 | 1,761 | 83 | 0 |
| 31 Dec 21 | 6,051 | 1,924 | 65 | 0 |
| 30 Sep 21 | 6,260 | 2,032 | 65 | 0 |
| 30 Jun 21 | 6,030 | 1,685 | 73 | 0 |
| 31 Mar 21 | 4,946 | 1,132 | 65 | 0 |
| 31 Dec 20 | 4,503 | 741 | 69 | 0 |
| 30 Sep 20 | 4,178 | 692 | 69 | 0 |
| 30 Jun 20 | 3,797 | 612 | 0 | 0 |
| 31 Mar 20 | 4,343 | 884 | 69 | 0 |
| 31 Dec 19 | 4,384 | 1,063 | 244 | 0 |
| 30 Sep 19 | 4,289 | 990 | 244 | 0 |
| 30 Jun 19 | 4,165 | 892 | 244 | 0 |
| 31 Mar 19 | 4,039 | 851 | 244 | 0 |
| 31 Dec 18 | 3,946 | 939 | 237 | 0 |
| 30 Sep 18 | 3,822 | 953 | 237 | 0 |
| 30 Jun 18 | 3,663 | 947 | 237 | 0 |
| 31 Mar 18 | 3,569 | 933 | 237 | 0 |
| 31 Dec 17 | 3,493 | 1,117 | 125 | 0 |
| 30 Sep 17 | 3,359 | 994 | 125 | 0 |
| 30 Jun 17 | 3,258 | 759 | 0 | 0 |
| 31 Mar 17 | 3,045 | 428 | 220 | 0 |
| 31 Dec 16 | 2,843 | 659 | 120 | 0 |
| 30 Sep 16 | 2,699 | 601 | 120 | 0 |
| 30 Jun 16 | 2,535 | 564 | 120 | 0 |
| 31 Mar 16 | 2,411 | 518 | 120 | 0 |
Kvalitetsintäkter: 539871 har inkomster av hög kvalitet.
Växande vinstmarginal: 539871 s nuvarande netto vinstmarginaler (19.7%) är högre än förra året (13.3%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: 539871 s intäkter har minskat med 8% per år under de senaste 5 åren.
Accelererande tillväxt: 539871 s intäktstillväxt under det senaste året ( 78.2% ) överstiger sitt 5-åriga genomsnitt ( -8% per år).
Resultat vs industri: 539871 vinsttillväxt under det senaste året ( 78.2% ) översteg Healthcare branschen 18.9%.
Avkastning på eget kapital
Hög ROE: 539871 s avkastning på eget kapital ( 27.8% ) anses vara hög.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/12 10:05 |
| Aktiekurs vid dagens slut | 2026/06/12 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Thyrocare Technologies Limited bevakas av 12 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Alka Katiyar | 360 ONE Capital Market Private Limited |
| Rahul Agarwal | CGS International |
| Kameswari V. S. Chavali | FirstCall Research |